-
公开(公告)号:JPH1067762A
公开(公告)日:1998-03-10
申请号:JP13116197
申请日:1997-05-21
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , HEITSCH HOLGER DR , NOELKEN GERHARD DR , WIRTH KLAUS DR , SCHOELKENS BERNWARD PROF DR
IPC: C07D277/60 , A61K31/38 , A61K31/395 , A61K31/41 , A61K31/425 , A61K31/428 , A61K31/53 , A61P43/00 , C07D253/10 , C07D277/62 , C07D277/64 , C07D277/66 , C07D277/68 , C07D277/70 , C07D277/74 , C07D277/82 , C07D417/12
Abstract: PROBLEM TO BE SOLVED: To produce a sulfur-containing compound which is a strong bradykinin antagonist and useful for treating and/or preventing allergies, inflammations, autoimmune diseases, shocks and pains. SOLUTION: This compound is represented by formula I one of X1 to X3 is C-O-R [R is a group represented by formula II (R and R are each H, a halogen, CN, etc.; R is H, a 1-5C alkyl, etc.; A is an aminocarboxyluc acid; R is H, etc.)]; others and X4 are N or CR (R is H, a halogen, etc.); R is same as R } and its physiologically permissible salt, e.g. 4-[3-(N-(3- methoxycinnamoylglycyl)-N-methylamino)-2,6-dichlorobenzyloxy]benzothia zole. The compound represented by formula I can be produced by passing a compound represented by formula III as a starting raw material through specific steps. Thereby, a pharmaceutical preparation for treating and/or preventing diseases caused by a mediator such as prostaglandins or leukotrienes.
-
公开(公告)号:DK0533058T3
公开(公告)日:2003-11-24
申请号:DK92115500
申请日:1992-09-10
Applicant: HOECHST AG
Inventor: KLEEMANN HEINZ-WERNER DR , HEITSCH HOLGER DR , WAGNER ADALBERT DR , GERHARDS HERMANN DR , SCHOELKENS BERNWARD PROF DR
IPC: A61K31/33 , A61K31/415 , A61K31/4184 , A61K31/435 , A61K31/4375 , A61K31/44 , A61K31/495 , A61K31/505 , A61P9/10 , A61P9/12 , C07D235/06 , C07D235/08 , C07D235/22 , C07D235/24 , C07D403/10 , C07D409/06 , C07D471/04 , C07D487/04 , C07D519/00
Abstract: Compounds of the formula (I) in which the symbols have the following meaning: X represents a monocyclic radical having 3, 4 or 5 ring atoms, R , R , R , R , R , R and R is, for example, an alkyl radical q is zero or 1 L is, for example, the methylene group A is the radical, for example, of a heterocycle are highly effective as antagonists of angiotensin II receptors. They can be used as pharmaceuticals or diagnostics.
-
公开(公告)号:AT183197T
公开(公告)日:1999-08-15
申请号:AT93105336
申请日:1993-03-31
Applicant: HOECHST AG
Inventor: BREIPOHL GERHARD DR , HENKE STEPHAN DR , KNOLLE JOCHEN DR , SCHOELKENS BERNWARD PROF DR , ALPERMANN HANS-GEORG DR , GERHARDS HERMANN DR , WIRTH KLAUS DR
Abstract: Peptides of the formula I Z - P - A - B - C - E - F - K - (D)Q - G- M- F' - I (I), in which Z is optionally substituted (cyclo)alk(ano)yl(sulphonyl), (C1-C8)-alkoxycarbonyl, (hetero)ar(o)yl(sulphonyl), carbamoyl, P is a direct linkage or a radical II -NR -(U)-CO- (II> in which R is H, methyl or a urethane protective group, U is (cyclo)(aryl)alkylidene, (hetero)arylidene or (CHR )n, R is hydrogen, (cyclo)alkyl, (hetero)aryl, or in which R and R form, together with the atoms carrying them, a ring system; A is defined as P; B is a basic amino acid in the L or D configuration, C is a compound of the formula IIIa or IIIb G'-G'-Gly (IIIa> G'-NH-(CH2)p-CO (IIIb> in which p is 2 to 8 and G' are, independently of one another, a radical of the formula IV -NR -CHR -CO- (IV> in which R and R form, together with the atoms carrying them, a heterocyclic ring system; E is the residue of a neutral, acid or basic, aliphatic or alicyclic-aliphatic amino acid; F are, independently of one another, the radical of a neutral, acid or basic, aliphatic or aromatic amino acid, or a direct linkage; (D)Q is D-Tic, D-Phe, D-Dic, D-Thi or D-Nal, or a radical of the formula (V) in which X is O, S or a direct linkage, and R is H, (cyclo)alkyl or aryl(alkyl), G is defined as G' above or is a direct linkage; F' is defined as F, is a radical -NH-(CH2)q- with q = 2 to 8 or, if G is not a direct linkage, can be a direct linkage, and I is -OH, -NH2 or NHC2H5; K is the radical -NH-(CH2)x-CO- with x = 1-4 or is a direct linkage, and M is defined as F and their physiologically tolerated salts are described. They have excellent bradykinin-antagonistic action. They are obtained by reacting a fragment with a C-terminal free carboxyl group or its activated derivative with an appropriate fragment with an N-terminal free amino group, or by assembling the peptide stepwise, eliminating one or more protective groups temporarily introduced where appropriate to protect other functionalities in the compound obtained in this way, and converting the compounds of the formula I obtained in this way where appropriate into their physiologically tolerated salt.
-
公开(公告)号:DK0503162T3
公开(公告)日:1998-12-07
申请号:DK91122406
申请日:1992-01-01
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , ENGLERT HEINRICH DR , KLEEMANN HEINZ-WERNER DR , GERHARDS HERMANN DR , SCHOELKENS BERNWARD PROF DR , BECKER REINHARD DR , LINZ WOLFGANG DR , CAILLE JEAN-CLAUDE , VEVERT JEAN-PAUL
IPC: A61K31/40 , A61K31/415 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/505 , A61K31/535 , A61K31/54 , A61K31/64 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/34 , C07D207/36 , C07D233/54 , C07D233/66 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/02 , C07D255/02 , C07D257/02 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D521/00
Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.
-
公开(公告)号:DE19712636A1
公开(公告)日:1998-10-01
申请号:DE19712636
申请日:1997-03-26
Applicant: HOECHST AG
Inventor: LANG HANS JOCHEN DR , JANSEN HANS-WILLI DR , SCHWARK JAN-ROBERT DR , KLEEMANN HEINZ-WERNER DR , JUNG OLIVER , SCHAEFER HANS-LUDWIG DR , LINZ WOLFGANG DR , KRAMER WERNER PROF DR DR , SCHOELKENS BERNWARD PROF DR , FALK EUGEN DR
IPC: A61K31/166 , A61K31/155 , A61K31/415 , A61K31/42 , A61K31/425
Abstract: Use of sodium/proton exchange inhibitors in the preparation of a medicament for treatment of raised blood lipid levels is new.
-
公开(公告)号:DE19546938A1
公开(公告)日:1997-06-19
申请号:DE19546938
申请日:1995-12-15
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , BREIPOHL GERHARD DR , HEITSCH HOLGER DR , GERHARDS HERMANN DR , NOELKEN GERHARD DR , WIRTH KLAUS DR , SCHOELKENS BERNWARD PROF DR
Abstract: 1-Carbamoyl-4-piperidinecarbonyl di- and tripeptides (I) and their salts are new: R = H, 2-6C alkyl, NR R or -N(R )=C(NHR )(NHR ); R = 1-10C alkyl, 2-10C alkenyl, 3-10C alkynyl or -(CH2)m-B-(CH2)n-R (all optionally monosubstituted by CO2R or by 1 or more halo), OR , 3-8C cycloalkyl, 4-10C cycloalkyl-1-4C alkyl, 5-10C cycloalkyl-2-4C alkenyl, 5-10C cycloalkyl-2-4C alkynyl or 6-10C aryl (optionally mono- or disubstituted by halo, 1-4C alkoxy, NO2 or CN); R = H, 1-8C alkyl, 3-8C cycloalkyl, phenyl, benzyl, 1-8C alkoxy-CO- or 1-4C alkyl-6-10C aryloxy-CO-; R = H, 1-6C alkyl, 3-8C cycloalkyl, 2-4C alkenyl or 2-4C alkynyl; R = H, 1-6C alkyl, 3-8C cycloalkyl, phenyl or benzyl; B = O, NR or S; n = 1-5; m = 0-5; o, p = 1-10; A1 = a bond, Phe, 2-, 3- or 4-Cl- or 2-, 3- or 4-F-phenylalanine, Tyr, Tyr(OMe), Thi, Gly, Cha, Leu, Ile, Val, Nle or Phg; A2 = a bond, Gly, Ser, Hser, Lys, Leu, Val, Nle, Ile or Cys; and A3, A4 = a bond or a heterocyclic group of e.g. formula (A) to (C).
-
公开(公告)号:DE59008959D1
公开(公告)日:1995-06-01
申请号:DE59008959
申请日:1990-09-03
Applicant: HOECHST AG
Inventor: ENGLERT HEINRICH CHRISTIAN DR , LANG HANS-JOCHEN DR , LINZ WOLFGANG DR , SCHOELKENS BERNWARD PROF DR , SCHOLZ WOLFGANG DR
IPC: C07C279/22 , A61K31/155 , A61K31/18 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/445 , A61K31/455 , A61K31/535 , A61K31/5375 , A61P9/06 , A61P9/08 , A61P9/10 , C07C277/00 , C07C279/10 , C07C311/15 , C07C311/47 , C07C317/42 , C07C317/44 , C07C323/60 , C07C323/62 , C07C323/65 , C07C323/67 , C07D209/08 , C07D211/28 , C07D295/14 , C07D295/155 , C07D295/195 , C07D295/22 , C07D295/26
Abstract: Benzoylguanidines of the formula I (* CHEMICAL STRUCTURE *) (I) where R(1) or R(2) is equal to R(6)-S(O)n- or R(7)R(8)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)-S(O)n or R(7)R(8)N- and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(7) and R(8) are equal to alkyl or phenylalkyl or phenyl, and in which R(7) and R(8) may also together be a C4-C7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system, and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(4) are together an alkylene chain, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.
-
公开(公告)号:AT121738T
公开(公告)日:1995-05-15
申请号:AT90116859
申请日:1990-09-03
Applicant: HOECHST AG
Inventor: ENGLERT HEINRICH CHRISTIAN DR , LANG HANS-JOCHEN DR , LINZ WOLFGANG DR , SCHOELKENS BERNWARD PROF DR , SCHOLZ WOLFGANG DR
IPC: C07C279/22 , A61K31/155 , A61K31/18 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/445 , A61K31/455 , A61K31/535 , A61K31/5375 , A61P9/06 , A61P9/08 , A61P9/10 , C07C277/00 , C07C279/10 , C07C311/15 , C07C311/47 , C07C317/42 , C07C317/44 , C07C323/60 , C07C323/62 , C07C323/65 , C07C323/67 , C07D209/08 , C07D211/28 , C07D295/14 , C07D295/155 , C07D295/195 , C07D295/22 , C07D295/26
Abstract: Benzoylguanidines of the formula I (* CHEMICAL STRUCTURE *) (I) where R(1) or R(2) is equal to R(6)-S(O)n- or R(7)R(8)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)-S(O)n or R(7)R(8)N- and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(7) and R(8) are equal to alkyl or phenylalkyl or phenyl, and in which R(7) and R(8) may also together be a C4-C7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system, and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(4) are together an alkylene chain, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.
-
公开(公告)号:DE4010797A1
公开(公告)日:1991-10-10
申请号:DE4010797
申请日:1990-04-04
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , HENNING RAINER DR , GERHARDS HERMANN DR , SCHOELKENS BERNWARD PROF DR
IPC: A61K31/415 , A61K31/38 , A61K31/40 , A61K31/41 , A61K31/4155 , A61K31/4164 , A61K31/423 , A61K31/437 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/495 , A61K31/505 , A61K31/519 , A61P9/12 , A61P29/00 , A61P43/00 , C07D233/64 , C07D233/84 , C07D233/90 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D413/06 , C07D471/04 , C07D487/04
Abstract: The invention relates to compounds of the formula in which X, Y and Z are identical or different and are N or CR , R and R are as defined in the description, L is an alkylene radical, q = 0 or 1, and A is the radical of a fused heterobicycle. The invention furthermore relates to a method for the preparation of the abovementioned compounds, to compositions containing them, and to their use.
-
公开(公告)号:SI0795547T1
公开(公告)日:2000-10-31
申请号:SI9730063
申请日:1997-02-27
Applicant: HOECHST AG
Inventor: HEITSCH HOLGER DR , WAGNER ADALBERT DR , WIRTH KLAUS DR , SCHOELKENS BERNWARD PROF DR , NOELKEN GERHARD DR
IPC: A61K31/47 , A61P43/00 , C07D215/48 , C07D215/26
Abstract: 8-(3-(Aminoalkoxy)-benzyloxy)-quinoline compounds of formula (I) and their salts are new. R1-R3 = H, halo, CHO, COOH, 1-5C alkyl, 6-10C aryl, 1-3C alkyl-(6-10C) aryl, 3-8C cycloalkyl or 1-3C alkoxycarbonyl; R4, R5 = H, halo, NO2, CN, 1-3C alkoxy or 1-3C alkylthio; R6 = H, 1-3C alkyl, 3-5C alkylalkenyl (sic) or 1-3C alkyl-6-10C aryl; R7 = H, 1-6C alkanoyl, alkanoyl (substituted by 1-3C alkoxy, alkylcarbamoyl or aryl), 3-7C alkenoyl, 3-8C cycloalkylcarbonyl, 5-7C cycloalkenylcarbonyl, 1-3C alkoxycarbonyl, aryloxycarbonyl, 6-12C aroyl (optionally substituted by 1-3C alkoxy or halo), alkenoyl (substituted by aryl (optionally substituted by 1-3C alkoxy, 1-3C alkylenedioxy, NO2, CN, halo, 1-3C haloalkyl, hetero-3-8C cycloalkyl (sic), NH2, 1-4C alkylamino, 6-12C heteroaryl-alkanoylamino, aroylamino, 6-12C heteroarylcarbonylamino, 1-5C alkylsulphonylamino, 1-5C alkylureido, alkanoyl, 1-5C alkoxycarbonyl, 1-5C alkylcarbamoyl or arylcarbamoyl), 2-5C acylamino-arylcinnamoyl, 1-3C alkoxycarbonylamino-arylcinnamoyl, 1-4C alkylaminocarbonylaminocinnamoyl, aryl-1-5C alkoxycarbonyl, 1-5C alkylcarbamoyl, arylcarbamoyl, aroylcarbamoyl, alkylsulphonyl, arylsulphonyl, aryl-alkylsulphonyl or phthaloyl (for R6=R7(sic)); n = 1-8; alkyl has 1-6C, aryl has 6-12C, alkanoyl has 2-6C, and alkenoyl has 3-6C unless specified other wise.
-
-
-
-
-
-
-
-
-